RE:RE:RE:RE:RE:Hexo payed 927M for redecan If Nextleaf is turning a profit at $30 cartidges then the IP has been proven. Their competitive advantage on a small scale is great, the fact that it's purposely designed to scale up makes it desireable to larger players.
There is a sizeable community of cannabis snobs who think paying +$50 for a cartridge means better product. As Pure Sunfarms exposed, that group is completely dwarfed by the overwhelming consumer base that wants quality affordable options. I expect these SKU's to move quickly and exponentially as they enter various provincial markets.
If the FDA gets around to finalizing CBD regs, lookout.